Flamma

Executive Summary

Flamma Group is a privately held, award-winning CDMO headquartered in Milan, Italy, founded in 2003. The company specializes in the development and manufacturing of small molecule Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCEs), and intermediates, with a global cGMP network spanning facilities in Italy, the USA, and China. By offering a secure, end-to-end supply chain from early-stage development through commercial-scale manufacturing, Flamma positions itself as a high-value partner for accelerating drug development timelines. Despite being classified as pre-clinical, the company's established operational footprint and focus on both small molecules and biologics/drug delivery underscore its versatility in serving the pharmaceutical industry. As a private entity with no disclosed financials, Flamma's growth trajectory is tied to its ability to secure long-term manufacturing contracts and expand its capacity. The CDMO market remains competitive, but Flamma's multi-regional presence provides supply chain resilience, a key differentiator. The company's conviction score is moderate, reflecting its solid operational base yet limited visibility into near-term financial performance or major pipeline catalysts. Key upcoming catalysts include potential capacity expansions to meet demand, strategic partnerships with biotech firms, and possible regulatory upgrades or certifications that enhance its service offerings.

Upcoming Catalysts (preview)

• Q2 2026Capacity expansion at existing facilities (e.g., China or Italy)70% success
• Q4 2026New strategic partnership with a major pharma or biotech50% success
• Q3 2026Expansion into biologics or advanced drug delivery services40% success